Z Tech
Purchase-Price Allocation
Goodwill
$12.4M
Intangibles
$5.6M
Assets Acquired
$19.2M
Liabilities Assumed
$1.7M
Deferred Tax Liability
$1.1M
2 years of history · ending 2024-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 2.00% | 6.30% | 6.10% | 5.60% | 0.00% | 0.00% |
| Foreign Rate Differential | -0.20% | -0.10% | — | — | -0.70% | -1.40% |
| Other Adjustments | 1.10% | 0.40% | 0.00% | -1.00% | -0.50% | 0.00% |
| Nondeductible Expenses | -0.20% | -10.70% | 1.50% | -0.40% | -0.20% | -6.50% |
| Valuation Allowance Change | -53.30% | -17.00% | -21.30% | -20.10% | 56.60% | -11.30% |
| Tax Law Change | 0.00% | 1.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Effective Tax Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.40% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | — | — | $15.1M | $10.8M | — | −$425.4K |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$12.4M
Intangibles
$5.6M
Assets Acquired
$19.2M
Liabilities Assumed
$1.7M
Deferred Tax Liability
$1.1M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).